ZYME on Nasdaq
Zymeworks
Logo: Unknown author Unknown author, CC BY-SA 4.0, via Wikimedia Commons5
Canadian biotechnology company
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure.3 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
2003Founded1
Compare with ZEVRA THERAPEUTICS, INC., Theravance Biopharma, Inc. or ImmunoGen Inc., or pick any stock.
- TickerZYME on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersVancouver1
- Websitewww.zymeworks.com
- Legal formDelaware corporation1
- LEI894500AHOYAGYLYZJL674
- StatusActive4
- LEI statusLapsed (not renewed)4
- Registered address108 Patriot Drive, Suite A, 19709 Middletown, United States4
- Registered withDivision of Corporations, Department of State, 67871124
See how the biggest companies compare on our leaderboards
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-87.3%Operating margin7
-76.6%Net margin7
38.9%Revenue growth, 20257
-30.2%Return on equity7
-$34.5MFree cash flow7
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs99¢$104.6M
- Income tax1¢$1.4M
Out of $106.0M in revenue.7 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development collaborations (note 11) | $106.0M | $76.3M | $76.0M |
| Research and development | $137.0M | $134.6M | $143.6M |
| General and administrative | $61.5M | $61.5M | $70.4M |
| Impairment on IPR&D (note 6) | $0 | $17.3M | $0 |
| Total operating expenses | $198.5M | $213.4M | $214.1M |
| Loss from operations | -$92.5M | -$137.1M | -$138.1M |
| Interest income | $13.4M | $19.9M | $19.7M |
| Other (expense) income, net (note 12) | -$559.0K | $558.0K | -$894.0K |
| Total other income, net | $12.8M | $20.5M | $18.8M |
| Loss before income taxes | -$79.8M | -$116.6M | -$119.2M |
| Income tax (expense) recovery (note 13) | -$1.4M | -$6.1M | $568.0K |
| Net loss | -$81.1M | -$122.7M | -$118.7M |
| Unrealized income (loss) on available for sale securities, net of tax of nil (note 5) | $873.0K | -$349.0K | $56.0K |
| Total other comprehensive income (loss) | $873.0K | -$349.0K | $56.0K |
| Comprehensive loss | -$80.3M | -$123.0M | -$118.6M |
| Basic (in dollars per share) | -$1.08 | -$1.62 | -$1.72 |
| Diluted (in dollars per share) | -$1.08 | -$1.62 | -$1.72 |
| Basic (in shares) | 75.4M shares | 75.8M shares | 68.9M shares |
| Diluted (in shares) | 75.4M shares | 75.9M shares | 68.9M shares |
| Unrealized loss on available for sale securities, tax | $0 | $0 | $0 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2024-07-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $41.2M | $66.1M | |||
| Short-term marketable securities (note 5) | $187.6M | $159.7M | |||
| Accounts receivable | $4.6M | $55.8M | |||
| Prepaid expenses and other current assets | $15.3M | $18.9M | |||
| Total current assets | $248.8M | $300.5M | |||
| Long-term marketable securities (note 5) | $41.8M | $98.4M | |||
| Long-term prepaids and other assets | $6.7M | $8.9M | |||
| Deferred tax asset (note 13) | $4.7M | $4.4M | |||
| Property and equipment, net (note 7) | $15.5M | $17.6M | |||
| Operating lease right-of-use assets (note 14) | $15.7M | $16.7M | |||
| Intangible assets, net (note 8) | $1.4M | $4.6M | |||
| Goodwill (note 6) | $12.0M | $12.0M | |||
| Total assets | $346.5M | $463.1M | |||
| Accounts payable and accrued liabilities (note 9) | $36.3M | $59.8M | |||
| Income tax payable (note 13) | $83.0K | $128.0K | |||
| Current portion of operating lease liability (note 14) | $3.5M | $2.7M | |||
| Deferred revenue and other consideration (note 11) | $2.4M | $25.6M | |||
| Total current liabilities | $42.3M | $88.3M | |||
| Long-term portion of operating lease liability (note 14) | $14.8M | $15.7M | |||
| Deferred revenue (note 11) | $14.6M | $14.6M | |||
| Other long-term liabilities (note 9) | $278.0K | $923.0K | |||
| Deferred tax liability (note 13) | $6.0M | $4.8M | |||
| Total liabilities | $78.0M | $124.3M | |||
| Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2025 and December 31, 2024 (74,638,413 and 68,964,319 shares issued and outstanding at December 31, 2025 and 2024, respectively (note 10b). | $1.1B | $1.0B | |||
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2025 and December 31, 2024 (note 10b). | $0 | $0 | |||
| Exchangeable shares, no par value, 553,184 issued and outstanding shares at December 31, 2025 (December 31, 2024: 570,637) (note 10b). | $7.9M | $8.2M | |||
| Additional paid-in capital | $114.6M | $152.2M | |||
| Accumulated other comprehensive loss | -$6.1M | -$7.0M | |||
| Accumulated deficit | -$953.2M | -$830.3M | |||
| Total stockholders equity | $268.5M | $338.8M | $464.8M | ||
| Total liabilities and stockholders equity | $346.5M | $463.1M | |||
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 900.0M shares | 900.0M shares | |||
| Common shares, issued (in shares) | 74.6M shares | 69.0M shares | |||
| Common shares, outstanding (in shares) | 74.6M shares | 69.0M shares | |||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Preferred stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | |||
| Preferred stock, shares issued (in shares) | 1 shares | 1 shares | |||
| Preferred stock, shares outstanding (in shares) | 1 shares | 1 shares | |||
| Exchangeable stock, shares issued (in shares) | 553.2K shares | 570.6K shares | |||
| Exchangeable shares, shares outstanding (in shares) | 553.2K shares | 570.6K shares |
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2024-07-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $41.2M | $66.1M | ||||
| Short-term marketable securities (note 5) | $187.6M | $159.7M | ||||
| Accounts receivable | $4.6M | $55.8M | ||||
| Prepaid expenses and other current assets | $15.3M | $18.9M | ||||
| Total current assets | $248.8M | $300.5M | ||||
| Long-term marketable securities (note 5) | $41.8M | $98.4M | ||||
| Long-term prepaids and other assets | $6.7M | $8.9M | ||||
| Deferred tax asset (note 13) | $4.7M | $4.4M | ||||
| Property and equipment, net (note 7) | $15.5M | $17.6M | ||||
| Operating lease right-of-use assets (note 14) | $15.7M | $16.7M | ||||
| Intangible assets, net (note 8) | $1.4M | $4.6M | ||||
| Goodwill (note 6) | $12.0M | $12.0M | ||||
| Total assets | $346.5M | $463.1M | ||||
| Accounts payable and accrued liabilities (note 9) | $36.3M | $59.8M | ||||
| Income tax payable (note 13) | $83.0K | $128.0K | ||||
| Current portion of operating lease liability (note 14) | $3.5M | $2.7M | ||||
| Deferred revenue and other consideration (note 11) | $2.4M | $25.6M | ||||
| Total current liabilities | $42.3M | $88.3M | ||||
| Long-term portion of operating lease liability (note 14) | $14.8M | $15.7M | ||||
| Deferred revenue (note 11) | $14.6M | $14.6M | ||||
| Other long-term liabilities (note 9) | $278.0K | $923.0K | ||||
| Deferred tax liability (note 13) | $6.0M | $4.8M | ||||
| Total liabilities | $78.0M | $124.3M | ||||
| Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2025 and December 31, 2024 (74,638,413 and 68,964,319 shares issued and outstanding at December 31, 2025 and 2024, respectively (note 10b). | $1.1B | $1.0B | ||||
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2025 and December 31, 2024 (note 10b). | $0 | $0 | ||||
| Exchangeable shares, no par value, 553,184 issued and outstanding shares at December 31, 2025 (December 31, 2024: 570,637) (note 10b). | $7.9M | $8.2M | ||||
| Additional paid-in capital | $114.6M | $152.2M | ||||
| Accumulated other comprehensive loss | -$6.1M | -$7.0M | ||||
| Accumulated deficit | -$953.2M | -$830.3M | ||||
| Total stockholders equity | $268.5M | $338.8M | $464.8M | $493.0M | ||
| Total liabilities and stockholders equity | $346.5M | $463.1M | ||||
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 900.0M shares | 900.0M shares | ||||
| Common shares, issued (in shares) | 74.6M shares | 69.0M shares | ||||
| Common shares, outstanding (in shares) | 74.6M shares | 69.0M shares | ||||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||||
| Preferred stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||||
| Preferred stock, shares issued (in shares) | 1 shares | 1 shares | ||||
| Preferred stock, shares outstanding (in shares) | 1 shares | 1 shares | ||||
| Exchangeable stock, shares issued (in shares) | 553.2K shares | 570.6K shares | ||||
| Exchangeable shares, shares outstanding (in shares) | 553.2K shares | 570.6K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$81.1M | -$122.7M | -$118.7M |
| Depreciation of property and equipment (note 7) | $3.7M | $4.2M | $7.5M |
| Amortization of intangible assets (note 8) | $4.1M | $4.5M | $2.7M |
| Stock-based compensation (note 10e) | $28.0M | $17.8M | $8.1M |
| Amortization and impairment of operating lease right-of-use assets | $3.4M | $2.5M | $7.1M |
| Impairment of acquired IPR&D (note 6) | $0 | $17.3M | $0 |
| Deferred income tax expense (recovery) (note 13) | $945.0K | $691.0K | -$757.0K |
| Change in fair value of contingent consideration liability (note 15) | $0 | -$1.9M | $630.0K |
| Change in fair value of investments in equity instruments | $0 | $0 | $667.0K |
| Unrealized foreign exchange loss (gain) | $532.0K | -$1.5M | -$31.0K |
| Accounts receivable | $51.2M | -$36.4M | $13.9M |
| Prepaid expenses and other current assets | $6.5M | -$2.5M | $4.3M |
| Accounts payable and accrued liabilities | -$23.6M | $14.3M | -$44.8M |
| Operating lease liabilities | -$3.3M | -$8.3M | -$3.7M |
| Deferred revenue and other consideration | -$23.2M | $3.6M | $3.7M |
| Income taxes payable | -$45.0K | -$1.7M | $970.0K |
| Net cash used in operating activities | -$33.0M | -$110.1M | -$118.3M |
| Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a) | $0 | $0 | $26.2M |
| Private placement (note 10a) | $5.0M | $0 | $49.9M |
| Issuance of common stock on exercise of stock options (note 10e) | $16.9M | $8.9M | $5.0M |
| Issuance of common stock through employee stock purchase plan (note 10f) | $1.4M | $930.0K | $820.0K |
| Purchases of common stock for retirement (note 10c) | -$41.7M | -$30.1M | $0 |
| Deferred financing fees | -$181.0K | -$174.0K | -$53.0K |
| Net cash (used in) / provided by financing activities | -$18.6M | -$20.4M | $81.9M |
| Purchases of marketable securities | -$196.1M | -$283.7M | -$553.2M |
| Proceeds from marketable securities | $225.1M | $325.6M | $350.1M |
| Acquisition of property and equipment | -$1.5M | -$2.0M | -$2.5M |
| Acquisition of intangible assets | -$831.0K | -$1.1M | -$1.6M |
| Net cash provided by / (used in) investing activities | $26.7M | $38.8M | -$207.3M |
| Effect of exchange rate changes on cash and cash equivalents | -$45.0K | $286.0K | $354.0K |
| Net change in cash and cash equivalents | -$24.9M | -$91.5M | -$243.4M |
| Net cash paid during the year for income taxes | $1.4M | $3.2M | $165.0K |
| Leased assets obtained in exchange for operating lease liabilities | $2.4M | $644.0K | $1.9M |
| Issuance of common stock upon exercise of pre-funded warrants (note 10d) | $49.9M | $0 | $0 |
| Purchases of common stock not settled | $464.0K | $0 | $0 |
| Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities | $0 | $0 | $122.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Zymeworks sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Zymeworks
- Rubric Capital Management LP Filed SCHEDULE 13G/A on Zymeworks, latest May 15, 2026 (3 filings since Nov 13, 2024)
- PERCEPTIVE ADVISORS LLC Filed SCHEDULE 13G on Zymeworks, latest Apr 15, 2026 (4 filings since Feb 15, 2022)
- Morgan Stanley Filed SCHEDULE 13G/A on Zymeworks, latest Feb 12, 2026 (5 filings since Feb 11, 2022)
- EcoR1 Capital, LLC Filed SCHEDULE 13D/A on Zymeworks, latest Nov 19, 2025 (12 filings since Oct 28, 2022)
- BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13G/A on Zymeworks, latest Nov 14, 2025 (3 filings since Jan 3, 2023)
- Redmile Group, LLC Filed SCHEDULE 13G/A on Zymeworks, latest Nov 14, 2025 (8 filings since Aug 8, 2022)
- BlackRock Filed SCHEDULE 13G/A on Zymeworks, latest Jul 16, 2025 (2 filings since Jan 29, 2024)
- BAKER BROS. ADVISORS LP Filed SC 13G/A on Zymeworks, latest Feb 14, 2024 (3 filings since Feb 14, 2022)
- Bank of America Filed SC 13G/A on Zymeworks, latest Feb 14, 2023 (2 filings since Jan 31, 2022)
- EVENTIDE ASSET MANAGEMENT, LLC Filed SC 13G/A on Zymeworks, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Goldman Sachs Filed SC 13G/A on Zymeworks, latest Feb 10, 2023 (2 filings since Feb 11, 2022)
- Wellington Management Company Filed SC 13G/A on Zymeworks, latest Feb 6, 2023 (2 filings since Feb 4, 2022)
- Zymeworks Vancouver, British Columbia, Canada
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Zymeworks reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $36.8M8 Dec 31, 2021 | $22.5M8 Dec 31, 2020 | +63.6% |
| Accumulated depreciation | $14.1M8 Dec 31, 2021 | $10.3M8 Dec 31, 2020 | +36.1% |
| Property and equipment, net | $22.8M8 Dec 31, 2021 | $12.2M8 Dec 31, 2020 | +87.0% |
| Operating-lease assets (leased space) | $27.0M8 Dec 31, 2021 | $5.4M8 Dec 31, 2020 | +397.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $201.9M8 Dec 31, 2021 | $242.0M8 Dec 31, 2020 | −16.6% |
| Marketable securities, current | $50.7M8 Dec 31, 2021 | $184.3M8 Dec 31, 2020 | −72.5% |
| Marketable securities, non-current | $718.0K14 Dec 31, 2020 | $014 Dec 31, 2019 | |
| Long-term investments | $886.0K8 Dec 31, 2021 | $25.9M8 Dec 31, 2020 | −96.6% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $12.0M8 Dec 31, 2021 | $12.0M8 Dec 31, 2020 | 0% |
| Indefinite-lived intangibles (excluding goodwill) | $17.6M8 Dec 31, 2021 | $17.6M8 Dec 31, 2020 | 0% |
| Finite-lived intangibles, gross | $16.4M14 Dec 31, 2020 | $13.0M14 Dec 31, 2019 | +26.2% |
| Accumulated amortization | $13.9M8 Dec 31, 2021 | $11.1M8 Dec 31, 2020 | +25.2% |
| Finite-lived intangibles, net | $3.8M8 Dec 31, 2021 | $5.3M8 Dec 31, 2020 | −27.6% |
Leadership
Who has led Zymeworks, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20052010201520202025
- Chief executive officerKenneth Galbraith Jan 18, 2022 to Jan 18, 202215
- Chief executive officerKenneth Galbraith Dec 23, 2022 to now16
- Chief executive officerAli Tehrani Jan 2, 2019 to Jul 16, 202117
- ChairKenneth Galbraith Jan 18, 2022 to Jan 18, 202215
- ChairKenneth Galbraith Dec 23, 2022 to now16
- PresidentNeil A. Klompas Jan 6, 2023 to Mar 14, 202318
- PresidentKenneth Galbraith Jan 18, 2022 to Jan 18, 202215
- Chief financial officerChristopher Astle Mar 4, 2022 to Mar 11, 202219
- Chief financial officerChristopher Astle Dec 14, 2022 to Jan 8, 202420
- Chief financial officerNeil A. Klompas Jan 2, 2019 to Jan 7, 202221
- Chief operating officerMark Hollywood Jan 13, 2026 to now22
- Chief operating officerNeil A. Klompas Jan 6, 2023 to Mar 14, 202318
- Chief operating officerNeil A. Klompas Jan 7, 2022 to Jul 5, 202223
Board members and other officers (41)
- SVP & Chief Medical OfficerSabeen Mekan Feb 2, 2026 to now24
- OfficerAdam Schayowitz Apr 10, 2026 to now25
- EVP, Chief Business OfficerScott Platshon Apr 10, 2026 to now26
- EVP, Chief Bus & Fin OfficerLeone D. Patterson Sep 3, 2024 to now27
- Chief Scientific OfficerPaul Andrew Moore Jan 6, 2023 to now28
- Chief Scientific OfficerPaul Andrew Moore Jul 19, 2022 to Jul 19, 202229
- Chief Medical OfficerNeil Josephson Nov 14, 2022 to Dec 23, 202230
- Chief Commercial OfficerJames Priour Feb 3, 2021 to Jul 8, 202131
- Interim Chief Medical OfficerNeil Josephson May 25, 2021 to Nov 14, 202232
- Chief Scientific OfficerAnthony J. Polverino Jan 2, 2019 to Jan 7, 202233
- OfficerDavid Kai Yuen Poon Jan 2, 2019 to May 8, 201934
- Chief Medical OfficerDiana Hausman Jan 2, 2019 to Mar 12, 202135
- Chief People OfficerKathryn O'Driscoll Oct 22, 2019 to Jul 8, 202136
- Board memberBrian N. Cherry Jan 13, 2026 to now37
- Board memberOleg Nodelman Feb 18, 2025 to now38
- Board memberGregory Austin Ciongoli Aug 12, 2025 to now39
- Board memberRobert E. Landry Aug 12, 2025 to now40
- Board memberAlessandra Cesano Feb 9, 2024 to now41
- Board memberScott Platshon Mar 4, 2024 to Mar 4, 202442
- Board memberNeil Gallagher Apr 2, 2024 to Dec 12, 202443
- Board memberCarlos Campoy Jun 30, 2023 to now44
- Board memberNancy Davidson Dec 8, 2023 to Dec 12, 202445
- Board memberHollings Renton Dec 23, 2022 to Dec 8, 202346
- Board memberKelvin Neu Dec 23, 2022 to now47
- Board memberKenneth Hillan Dec 23, 2022 to Dec 8, 202348
- Board memberLota S. Zoth Dec 23, 2022 to Dec 23, 202249
- Board memberNatalie Sacks Dec 23, 2022 to Dec 23, 202250
- Board memberSusan Mahony Dec 23, 2022 to now51
- Board memberTroy Cox Dec 23, 2022 to Dec 12, 202452
- Board memberFelix Baker Mar 16, 2020 to May 12, 202053
- Board memberJulian Baker Mar 16, 2020 to May 12, 202053
- Board memberKelvin Neu Mar 16, 2020 to May 7, 202154
- Board memberL.p. 667 Mar 16, 2020 to May 12, 202053
- Board memberAli Tehrani Jan 2, 2019 to Jul 16, 202117
- Board memberHollings Renton Jan 2, 2019 to May 7, 202155
- Board memberKenneth Hillan Jan 2, 2019 to May 7, 202156
- Board memberLota S. Zoth Jan 2, 2019 to May 7, 202157
- Board memberNatalie Sacks Jan 2, 2019 to May 7, 202158
- Board memberNick Bedford Jan 2, 2019 to May 8, 201959
- Board memberSusan Mahony Jun 11, 2019 to May 7, 202160
- Board memberTroy Cox Jun 11, 2019 to May 7, 202161
Named in SEC Form D filings
People the company listed in its private-offering notices.
Products and brands
- medication
Listed on Wikidata.1
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Zymeworks Biopharmaceuticals Inc. Washington6
- Zymeworks Lifesciences Pte. Ltd. Singapore6
- Zymeworks Management Inc. (UK Establishment) United Kingdom6
- Zymeworks Pharmaceuticals Limited Ireland6
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Sep 23, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation63
- Aug 25, 20268-K Regulation FD disclosure; Other events64
- Aug 6, 20268-K Results of operations; Regulation FD disclosure65
- Jun 29, 20268-K Entered a material agreement; Regulation FD disclosure66
- May 14, 20268-K Regulation FD disclosure; Other events67
- May 7, 20268-K Results of operations; Regulation FD disclosure68
- Apr 1, 20268-K Executive or director change69
- Mar 2, 20268-K Results of operations; Regulation FD disclosure70
- Mar 2, 20268-K Entered a material agreement; New debt or obligation; Regulation FD disclosure71
- Jan 12, 20268-K Results of operations; Executive or director change; Other events72
- Dec 30, 20258-K Shareholder vote73
- Nov 18, 20258-K Executive or director change; Regulation FD disclosure; Other events74
- Jan 18, 2022New chief executive Kenneth Galbraith becomes CEO15
- Jan 2, 2019New chief executive Ali Tehrani becomes CEO17
- 2003Founded Founded1
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.26) a share, on Nov 6, 2025.75
When it reported results
- Aug 6, 2026Reported quarterly or annual results65
- May 7, 2026Reported quarterly or annual results68
- Mar 2, 2026Reported quarterly or annual results70
- Jan 12, 2026Reported quarterly or annual results72
- Nov 6, 2025Reported quarterly or annual results76
- Aug 7, 2025Reported quarterly or annual results77
- May 8, 2025Reported quarterly or annual results78
- Mar 5, 2025Reported quarterly or annual results79
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
454 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 138 major events, 135 insider forms, 59 large holders, 1 private raises, 99 other. The latest 20:
- Oct 9, 20264 EDGAR
- Oct 9, 2026144 EDGAR
- Sep 23, 20268-K EDGAR
- Aug 25, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 6, 20264 EDGAR
- Jun 29, 20268-K EDGAR
- May 15, 20264 EDGAR
- May 15, 20263 EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 14, 20268-K EDGAR
- May 7, 202610-Q EDGAR
- May 7, 20268-K EDGAR
- Apr 15, 2026SCHEDULE 13G EDGAR
- Apr 10, 20264 EDGAR
- Apr 10, 20264 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 7, 20264 EDGAR
The 454 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
3 open-market trades by officers, directors and large owners since October 2021: 1 buys and 2 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2022 | Josephson NeilChief Medical Officer | Sale | 2,475 | $8.10 | $20.0K | Form 4 |
| Mar 10, 2022 | Klompas Neil AChief Operating Officer | Sale | 2,979 | $6.88 | $20.5K | Form 4 |
| Jan 7, 2022 | Josephson NeilChief Medical Officer | Buy | 5,000 | $14.28 | $71.4K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Rubric Capital Management LPSCHEDULE 13G/A, 3 filings Nov 13, 2024 to May 15, 202680
- PERCEPTIVE ADVISORS LLCSCHEDULE 13G, 4 filings Feb 15, 2022 to Apr 15, 202681
- Morgan StanleySCHEDULE 13G/A, 5 filings Feb 11, 2022 to Feb 12, 202682
- EcoR1 Capital, LLCSCHEDULE 13D/A, 12 filings Oct 28, 2022 to Nov 19, 202583
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 3 filings Jan 3, 2023 to Nov 14, 202584
- Redmile Group, LLCSCHEDULE 13G/A, 8 filings Aug 8, 2022 to Nov 14, 202585
- BlackRockSCHEDULE 13G/A, 2 filings Jan 29, 2024 to Jul 16, 202586
- BAKER BROS. ADVISORS LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202487
- Bank of AmericaSC 13G/A, 2 filings Jan 31, 2022 to Feb 14, 202388
- EVENTIDE ASSET MANAGEMENT, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202389
- Goldman SachsSC 13G/A, 2 filings Feb 11, 2022 to Feb 10, 202390
- Wellington Management CompanySC 13G/A, 2 filings Feb 4, 2022 to Feb 6, 202391
- Credit SuisseSC 13G/A, 2 filings Feb 14, 2022 to Feb 2, 202392
- Blue Falcons Fze AllSC 13D/A, 6 filings Apr 22, 2022 to Dec 28, 202293
- FMR LLCSC 13G/A, 2 filings Feb 9, 2022 to Mar 10, 202294
- MILLENNIUM MANAGEMENT LLCSC 13G, 1 filing Feb 10, 202295
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2024 | Kenneth GalbraithCEO , President & Chair | 63 | $654.8K | $5.3M96 |
| 2024 | Leone PattersonExec. VP, Chief Business Officer & CFO | 62 | $161.7K | $2.9M96 |
| 2023 | Kenneth GalbraithCEO , President & Chair | 63 | $625.5K | $3.4M96 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $50.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2023 | $50.0M | $50.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | $600.4M | 29.8% | No change |
| Rubric Capital Management LP | 7,000,000 | $183.0M | 1.7% | No change |
| BlackRock, Inc. | 4,251,030 | $111.1M | 0.0% | −302,858 |
| Perceptive Advisors LLC | 4,182,953 | $109.3M | 1.7% | +672,875 |
| Bvf Inc/il | 3,649,142 | $95.4M | 2.4% | −85,000 |
| Assenagon Asset Management S.A. | 2,504,054 | $65.5M | 0.0% | +1,776,068 |
| Morgan Stanley | 2,231,260 | $58.3M | 0.0% | −249,308 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,781,116 | $46.6M | 0.0% | −126,923 |
| Vanguard Capital Management LLC | 1,558,998 | $40.8M | 0.0% | −146,582 |
| Nextech Invest Ltd. | 1,113,946 | $29.1M | 1.4% | No change |
| State Street Corp | 1,088,216 | $28.4M | 0.0% | +76,439 |
| Dimensional Fund Advisors LP | 994,955 | $26.0M | 0.0% | −144,180 |
| Citadel Advisors LLC | 914,136 | $23.9M | 0.0% | −235,882 |
| Nomura Asset Management International Inc. | 889,802 | $23.3M | 0.0% | New |
| Fmr LLC | 702,568 | $18.4M | 0.0% | +35,415 |
| Geode Capital Management, LLC | 692,410 | $18.1M | 0.0% | +32,470 |
| Prosight Management, LP | 674,434 | $17.6M | 3.0% | +135,385 |
| Qube Research & Technologies Ltd | 593,590 | $15.5M | 0.0% | +81,653 |
| Vanguard Portfolio Management LLC | 510,032 | $13.3M | 0.0% | +10,157 |
| Redmile Group, LLC | 491,654 | $12.9M | 0.9% | No change |
| Capricorn Fund Managers Ltd | 486,529 | $12.7M | 1.0% | −520,681 |
| Goldman Sachs Group Inc | 470,822 | $12.3M | 0.0% | −128,664 |
| Arrowstreet Capital, Limited Partnership | 418,497 | $10.9M | 0.0% | −325,401 |
| Deutsche Bank Ag\ | 397,190 | $10.4M | 0.0% | −524,060 |
| Hillsdale Investment Management Inc. | 382,922 | $10.0M | 0.2% | +37,300 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Zymeworks is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARZymeworks BC Inc.2
- CIK0001403752
- Filer statusLarge accelerated filer2
- Incorporated inBritish Columbia, Canada2
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- Business addressSuite 800 - 114 East 4Th Avenue, Vancouver, A1 V5T 1G42
- Phone(604) 678-13882
- Shares outstanding57,892,785 as of Aug 2, 202297
- Public float$1.6B as of Jun 30, 202198
- On EDGAR sinceJun 14, 20072
- Filings516 in all: 8-K (163), 4 (101), 6-K (27), SC 13G/A (24), 3 (21), SC 13G (20), 425 (19), 10-Q (14)2
All 52 form types
CT ORDER (14), UPLOAD (9), 424B5 (8), CORRESP (8), D (8), 10-K (5), 8-K/A (5), S-8 (5), S-8 POS (5), EFFECT (4), SC 13D/A (4), 4/A (3), D/A (3), DEF 14A (3), DRS/A (3), DRSLTR (3), SUPPL (3), 25-NSE (2), 8-A12B (2), F-1/A (2), F-10/A (2), S-3ASR (2), SC 13D (2), SEC STAFF LETTER (2), 10-K/A (1), 15-12G (1), 424B4 (1), 424B7 (1), 424B8 (1), 6-K/A (1), CERT (1), CERTNYS (1), DEFM14A (1), DEL AM (1), DRS (1), F-1 (1), F-10 (1), F-10POS (1), F-X (1), POS AM (1), POSASR (1), REGDEX (1), S-3 (1), S-3/A (1)
- Latest filingsAnnual report (10-K) Feb 24, 2022
Quarterly report (10-Q) Aug 4, 2022
Proxy statement (DEF 14A) Mar 23, 2021
Latest 8-K (8-K) Oct 21, 2022
Links
- Websitewww.zymeworks.com1
- X (Twitter)x.com/ZymeworksInc1
- WikipediaZymeworks
- WikidataQ16968498
- SEC EDGARCIK 1403752
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataZymeworks on Wikidata
- 2SEC EDGARZymeworks filings on SEC EDGAR
- 3WikipediaZymeworks on Wikipedia
- 4
- 5Wikimedia CommonsZymeworks logo by Unknown author Unknown author, CC BY-SA 4.0
- 6
- 7SEC EDGARZymeworks 10-K for fiscal 2025
- 8SEC EDGARZymeworks 10-K for fiscal 2019
- 9SEC EDGARZymeworks 10-K for fiscal 2020
- 10SEC EDGARZymeworks 10-K for fiscal 2021
- 11SEC EDGARZymeworks 10-K for fiscal 2022
- 12SEC EDGARZymeworks 10-Q for fiscal 2026
- 13SEC EDGARZymeworks 10-Q for fiscal 2026
- 14SEC EDGARZymeworks 10-K for fiscal 2019
- 15
- 16
- 17SEC EDGARAli Tehrani, Chief executive officer
- 18SEC EDGARNeil A. Klompas, President
- 19
- 20
- 21
- 22
- 23
- 24
- 25SEC EDGARAdam Schayowitz, Officer
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34SEC EDGARDavid Kai Yuen Poon, Officer
- 35SEC EDGARDiana Hausman, Chief Medical Officer
- 36
- 37SEC EDGARBrian N. Cherry, Board member
- 38SEC EDGAROleg Nodelman, Board member
- 39
- 40SEC EDGARRobert E. Landry, Board member
- 41SEC EDGARAlessandra Cesano, Board member
- 42SEC EDGARScott Platshon, Board member
- 43SEC EDGARNeil Gallagher, Board member
- 44SEC EDGARCarlos Campoy, Board member
- 45SEC EDGARNancy Davidson, Board member
- 46SEC EDGARHollings Renton, Board member
- 47SEC EDGARKelvin Neu, Board member
- 48SEC EDGARKenneth Hillan, Board member
- 49SEC EDGARLota S. Zoth, Board member
- 50SEC EDGARNatalie Sacks, Board member
- 51SEC EDGARSusan Mahony, Board member
- 52SEC EDGARTroy Cox, Board member
- 53SEC EDGARFelix Baker, Board member
- 54SEC EDGARKelvin Neu, Board member
- 55SEC EDGARHollings Renton, Board member
- 56SEC EDGARKenneth Hillan, Board member
- 57SEC EDGARLota S. Zoth, Board member
- 58SEC EDGARNatalie Sacks, Board member
- 59SEC EDGARNick Bedford, Board member
- 60SEC EDGARSusan Mahony, Board member
- 61SEC EDGARTroy Cox, Board member
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69SEC EDGARExecutive or director change
- 70
- 71
- 72
- 73SEC EDGARShareholder vote
- 74
- 75NasdaqNasdaq calendar
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90SEC EDGARGoldman Sachs SC 13G/A on Zymeworks
- 91
- 92SEC EDGARCredit Suisse SC 13G/A on Zymeworks
- 93
- 94SEC EDGARFMR LLC SC 13G/A on Zymeworks
- 95
- 96
- 97
- 98